Advancement in study on long non⁃coding RNA and trastuzumab resistance of HER2 positive breast cancer

doi:10.16139/j.1007-9610.2020.03.019

Abstract

CLC Number:

R737.9

CAO Wei, CHEN Xiaosong, SHEN Kunwei. Advancement in study on long non⁃coding RNA and trastuzumab resistance of HER2 positive breast cancer[J]. Journal of Surgery Concepts & Practice, 2020, 25(03): 269-272.

Figures/Tables 2

References 25

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30. doi: 10.3322/caac.21442 URL
[2]	Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244(4905):707-712. doi: 10.1126/science.2470152 pmid: 2470152
[3]	Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785):177. doi: 10.1126/science.3798106 pmid: 3798106
[4]	Martine JPG, Marion P, Brian LJ, et al. Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer[J]. N Engl J Med, 2005, 353(16):1659-1672. doi: 10.1056/NEJMoa052306 URL
[5]	中国女医师协会临床肿瘤学专业委员会, 中国抗癌协会乳腺癌专业委员. 中国进展期乳腺癌共识(CABC 2015)[J]. 癌症进展, 2015, 13(3):223-245.
[6]	Ning S, Zhang J, Wang P, et al. Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers[J]. Nucleic Acids Res, 2016, 44(D1):D980-D985. doi: 10.1093/nar/gkv1094 URL
[7]	Chen G, Wang Z, Wang D, et al. LncRNADisease: a database for long-non-coding RNA-associated diseases[J]. Nucleic Acids Res, 2013, 41(Database issue):D983-D986. doi: 10.1093/nar/gks1099 URL
[8]	Xue X, Yang YA, Zhang A, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer[J]. Oncogene, 2016, 35(21):2746-2755. doi: 10.1038/onc.2015.340 pmid: 26364613
[9]	Lu R, Zhang J, Zhang W, et al. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer[J]. Cancer Biomark, 2018, 22(2):249-256. doi: 10.3233/CBM-170874 URL
[10]	Wu C, Luo J. Long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) enhances tamoxifen resistance in breast cancer cells via inhibiting mTOR signa-ling pathway[J]. Med Sci Monit, 2016,22:3860-3867.
[11]	Zhu HY, Bai WD, Ye XM, et al. Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1[J]. Biochem Biophys Res Commun, 2018, 496(4):1308-1313. doi: 10.1016/j.bbrc.2018.02.006 URL
[12]	Campos-Parra AD, Lopez-Urrutia E, Orozco Moreno LT, et al. Long non-coding RNAs as new master regulators of resistance to systemic treatments in breast cancer[J]. Int J Mol Sci, 2018, 19(9):2711. doi: 10.3390/ijms19092711 URL
[13]	Dong H, Wang W, Mo S, et al. Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation[J]. J Cell Mol Med, 2018, 22(10):4935-4947. doi: 10.1111/jcmm.13758 URL
[14]	Dong H, Wang W, Mo S, et al. SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88[J]. J Exp Clin Cancer Res, 2018, 37(1):202. doi: 10.1186/s13046-018-0875-3 URL
[15]	Li W, Zhai L, Wang H, et al. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer[J]. Oncotarget, 2016, 7(19):27778-27786. doi: 10.18632/oncotarget.8413 URL
[16]	Li GY, Wang W, Sun JY, et al. Long non-coding RNAs AC026904.1 and UCA1: a “one-two punch” for TGF-β-induced SNAI2 activation and epithelial-mesenchymal transition in breast cancer[J]. Theranostics, 2018, 8(10):2846-2861. doi: 10.7150/thno.23463 URL
[17]	李小燕, 贺靖, 邹强. 乳腺癌外泌体及相关miRNA的研究进展[J]. 外科理论与实践, 2018, 23(6):564-568.
[18]	金泽宇, 陈小松. 循环肿瘤DNA在乳腺癌诊治中应用的研究[J]. 外科理论与实践, 2018, 23(5):473-476.
[19]	Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J]. Cancer Cell, 2016, 29(5):653-668. doi: 10.1016/j.ccell.2016.03.004 URL
[20]	Dong H, Wang W, Chen R, et al. Exosome-mediated transfer of lncRNA-SNHG14 promotes trastuzumab chemoresistance in breast cancer[J]. Int J Oncol, 2018, 53(3):1013-1026.
[21]	Su X, Malouf GG, Chen Y, et al. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes[J]. Oncotarget, 2014, 5(20):9864-9876. doi: 10.18632/oncotarget.2454 URL
[22]	Lee J, Park HY, Kim WW, et al. Biological function of long noncoding RNA snaR in HER2-positive breast cancer cells[J]. Tumour Biol, 2017, 39(6):1010428317707374. doi: 10.1177/1010428317707374. doi: 10.1177/1010428317707374
[23]	Merry CR, Mcmahon S, Thompson CL, et al. Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer[J]. Breast Cancer Res Treat, 2015, 150(2):321-334. doi: 10.1007/s10549-015-3327-1 URL
[24]	Merry CR, Mcmahon S, Forrest ME, et al. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer[J]. Oncotarget, 2016, 7(33):53230-53244. doi: 10.18632/oncotarget.10637 URL
[25]	Yang F, Lyu S, Dong S, et al. Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics[J]. Onco Targets Ther, 2016, 9:761-772.

LncRNA	作用	参考文献
HOTAIR	在HER2阳性乳腺癌中过表达	Su等^[21]
snaR	在HER2阳性乳腺癌中表达显著上调	Lee等^[22]
linc-SLC39A10-10 linc-GJA1-2 linc-STARD6-2	在接受曲妥珠单抗治疗病人体内和HER2丢失的BT474细胞株中均异常表达	Merry等^[23]
linc-NDUFV3-1 linc-FCGR1B-7 linc-NADSYN1-1 linc-LRRC49-4 linc-C6orf145-3 linc-GABRA5-5 linc-VPS8-3	临床标本和细胞培养分析结果中均表现为,曲妥珠单抗耐药/敏感样本中差异表达	Merry等^[24]
LINC00636 LINC01405 ADARB2-AS1 ST8SIA6-AS1 LINC00511 DPP10-AS1	在HER2阳性乳腺癌中显著异常表达	Yang等^[25]

Advancement in study on long non⁃coding RNA and trastuzumab resistance of HER2 positive breast cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 25

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHU Qiaoli, MIAO Yiming, CHEN Xiaosong. Prognostic analysis of breast-conserving surgery or mastectomy in patients with stage Ⅰ-Ⅲ triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 371-377.
[2]	YANG Yi, YANG Xingxia, JIN Sili, ZHANG Xu, ZHU Juanying, CHEN Xiaosong. Clinical application of preoperative MRI examination in breast-conserving surgery for ductal carcinoma in situ [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 378-382.
[3]	DONG Jun, CUI Fengming, LIU Jun. Effects of silencing Ki-67 gene on doxorubicin resistance of breast cancer MCF-7/DOX cells [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 254-259.
[4]	GAO Weiqi, ZHANG Xu, WANG Zheng, ZHU Yifei, HUANG Jiahui, HONG Jin, ZHU Siji, CHEN Xiaosong, HUANG Ou, HE Jianrong, CHEN Weiguo, LI Yafen, SHEN Kunwei, XU Hua, WU Jiayi. Safety analysis of immediate breast reconstruction with deep inferior epigastric perforator after neoadjuvant treatment [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 147-151.
[5]	WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477.
[6]	ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472.
[7]	PAN Ruixin, CHEN Xiaosong, SHEN Kunwei. Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 463-467.
[8]	YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei. Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 421-428.
[9]	SHU Lan, CHEN Xiaosong. Multi-gene assay profiling testing in ER+/HER2- breast cancer: ASCO guidelinesinterpretation and Ruijin Hospital experience [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420.
[10]	HUANG Wei, Ll Hengyu, DING Xiaoyi. Value and application of intervention in advanced breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 411-415.
[11]	CAO Lu, ZHENG Siyue, CHEN Jiayi. Management of regional lymph nodes in early-stage breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410.
[12]	ZHOU Wenbin, TANG Xinyu, WANG Shui. Application of local microwave ablation in treatment of breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 403-405.
[13]	XIE Yanyan, LU Qing, DU Zhenggui. Endoscopic and robotic breast surgery: present and future—the experience of West China Hospital [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 396-402.
[14]	CHEN Yiding, WU Shijie. Surgical treatment of hereditary breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395.
[15]	WU Jiayi, LU Yujie, HE Jinguang, SHEN Kunwei, XU Hua. Post-mastectomy implant-based breast reconstruction [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 387-391.